An observational study in Cystic Fibrosis Related Diabetes, sponsored by Johns Hopkins University. Enrolling by invitation at 3 sites in United States. Open to participants aged 3 Months to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Johns Hopkins University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Diabetes Mellitus by Johns Hopkins University — 5 open to participants now, 8 under way, none of them phase 3. Diabetes Mellitus · Johns Hopkins University.
Among the 26 studies in Diabetes Mellitus by Johns Hopkins University, this one is one of 3 that started in 2008, is one of 3 observational ones, and was the 7th registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →5 of the 26 studies in Diabetes Mellitus by Johns Hopkins University are open now, in 1 country. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18+
Johns Hopkins University · Sites in United States
Ages 30–70
Johns Hopkins University · Sites in United States
Ages 18+
Johns Hopkins University
Ages 18+
By country, each count listing its studies:
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 3 Months to 99 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 3 2 · Phase 4 1
First in 2006; this study’s year is marked. 3 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,500 is above the median of 246 across 1,935 observational studies indexed under Diabetes Mellitus.
Median enrollment 94 across the 23 interventional studies, 1,500 across the 3 observational. Of the 17 that completed or were terminated, 8 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
Johns Hopkins University is the lead sponsor of 1,817 studies on the registry; 316 are open to participants now.
Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.
4 of the studies in Diabetes Mellitus by Johns Hopkins University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06607341Johns Hopkins UniversityCommunity Engagement Alliance Against Disparities | 2026-12-20 |
| NCT07674420Johns Hopkins UniversityWearable Insoles for Recurrent Diabetic Ulcer Prevention | 2027-01 |
| NCT05703386Johns Hopkins UniversityImaging the Pathogenesis of Cerebral Small Vessel Disease | 2027-03-31 |
| NCT06364644Johns Hopkins UniversityUnderstanding and Addressing Risks of Low Socioeconomic Status and Diabetes for Heart Failure | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 26 studies in Diabetes Mellitus by Johns Hopkins University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This research is being done to find the genes and other factors that are responsible for differences among persons with cystic fibrosis. We are particularly interested in the factors that relate to the development of Cystic Fibrosis Related Diabetes (CFRD).
The study is recruiting people with cystic fibrosis (CF). The medical record is being extracted, and a blood sample is taken for DNA. The DNA samples are tested for variation both at the cystic fibrosis transmembrane conductance regulator (CFTR) gene (the CF gene) and over the entire rest of the genome. Using large numbers of people with CF, and knowing who does and does not have CFRD, we identify genetic variations that associate with CFRD. Knowing these variations allows us to better understand the causes of CFRD, and with enough information, better to predict CFRD and identify people at particularly high or low risk of CFRD. People participating in this study also have the option to participate in related studies of other metabolic traits in CF such as over- and underweight.
Individuals affected with Cystic Fibrosis and family members
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Identification of Genes or other factors that influence the development of CFRD
Time frame: 5 years
Plan to share: No
The record gives a start of Apr 2008, a primary completion of Apr 2030 and a completion of Apr 2030. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.